ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
Dow Jones
44.544,66
-0,75%
Euro vs US Dollar
1,0366
0,04%
Bitcoin
99.699,36
-0,96%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Ovid Therapeutics Inc (OVID)

  7. Ovid Therapeutics Inc (OVID) News

OVID

Ovid Therapeutics (OVID)

Ovid Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:OVID
DatumZeitQuelleÜberschriftSymbolFirma
29/01/202515h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OVIDOvid Therapeutics Inc
16/12/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OVIDOvid Therapeutics Inc
16/12/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OVIDOvid Therapeutics Inc
02/12/202414h00GlobeNewswire Inc.Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual MeetingNASDAQ:OVIDOvid Therapeutics Inc
12/11/202414h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OVIDOvid Therapeutics Inc
12/11/202414h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
12/11/202414h00GlobeNewswire Inc.Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial ResultsNASDAQ:OVIDOvid Therapeutics Inc
31/10/202413h00GlobeNewswire Inc.Ovid Therapeutics to Host Investor EventNASDAQ:OVIDOvid Therapeutics Inc
26/09/202414h00GlobeNewswire Inc.Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with VigabatrinNASDAQ:OVIDOvid Therapeutics Inc
11/09/202423h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OVIDOvid Therapeutics Inc
11/09/202423h36Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:OVIDOvid Therapeutics Inc
11/09/202422h57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
11/09/202414h00GlobeNewswire Inc.Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future GrowthNASDAQ:OVIDOvid Therapeutics Inc
04/09/202414h00GlobeNewswire Inc.Ovid Therapeutics to Present at Upcoming September Investor ConferencesNASDAQ:OVIDOvid Therapeutics Inc
13/08/202414h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OVIDOvid Therapeutics Inc
13/08/202414h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
13/08/202414h00GlobeNewswire Inc.Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial ResultsNASDAQ:OVIDOvid Therapeutics Inc
08/08/202414h00GlobeNewswire Inc.Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development OfficerNASDAQ:OVIDOvid Therapeutics Inc
02/08/202423h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
30/07/202414h00GlobeNewswire Inc.Ovid Therapeutics to Present at Upcoming August Investor ConferencesNASDAQ:OVIDOvid Therapeutics Inc
23/07/202414h00GlobeNewswire Inc.Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and EpileptologistsNASDAQ:OVIDOvid Therapeutics Inc
10/07/202414h00GlobeNewswire Inc.eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant SeizuresNASDAQ:OVIDOvid Therapeutics Inc
01/07/202414h00GlobeNewswire Inc.Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous MalformationsNASDAQ:OVIDOvid Therapeutics Inc
17/06/202413h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
17/06/202412h55GlobeNewswire Inc.Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for SoticlestatNASDAQ:OVIDOvid Therapeutics Inc
07/06/202422h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
14/05/202423h19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OVIDOvid Therapeutics Inc
14/05/202414h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OVIDOvid Therapeutics Inc
14/05/202414h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
14/05/202414h00GlobeNewswire Inc.Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial ResultsNASDAQ:OVIDOvid Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:OVID

Kürzlich von Ihnen besucht

FX
EURJPY
Euro vs Yen
DBI
DAX
DAX
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
BAS
BASF
CCOM
US100
US Tech 100
NYSE
NKE
Nike
COIN
AVAXUSD
Avalanche
COIN
BTCUSD
Bitcoin
NASDAQ
AAPL
Apple
DBI
SDXP
SDAX
NASDAQ
GOOGL
Alphabet
TG
RHM
Rheinmetall
TG
ALV
Allianz
COIN
DOGEUSD
Dogecoin
AMEX
SPY
SPDR S&P 500
TG
BAYN
Bayer
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten